Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,187.70 +6.96 (+0.13%) Dow
38,884.26 +31.99 (+0.08%) Nasdaq
16,332.56 -16.69 (-0.10%) Bitcoin USD
62,923.89 -590.56 (-0.93%) CMC Crypto 200
1,308.29 -56.83 (-4.16%)
Sight Sciences, Inc. (SGHT)
| Previous close | 5.82 |
| Open | 5.82 |
| Bid | 4.11 x 200 |
| Ask | 5.70 x 400 |
| Day's range | 5.57 - 5.83 |
| 52-week range | 1.04 - 10.70 |
| Volume | |
| Avg. volume | 166,501 |
| Market cap | 281.064M |
| Beta (5Y monthly) | 2.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
MENLO PARK, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will present at the upcoming Bank of America Healthcare Conference, in Las Vegas, NV. Sight Sciences’ management is scheduled to present on Tuesday, May 14, 2024, at 8:15 am PT / 11:15 am ET. Interested parti
- GlobeNewswire
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the first quarter ended March 31, 2024, and reaffirmed financial guidance for full year 2024. Recent Business and Financial Highlights Generated first quarter 2024 total revenue of $19.3 mil
- GlobeNewswire
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it received a positive jury trial verdict of $34 million associated with the patent infringement case it filed on September 16, 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectiv
